163 related articles for article (PubMed ID: 38301413)
1. Peptide nanovaccine in melanoma immunotherapy.
Dehghankhold M; Sadat Abolmaali S; Nezafat N; Mohammad Tamaddon A
Int Immunopharmacol; 2024 Mar; 129():111543. PubMed ID: 38301413
[TBL] [Abstract][Full Text] [Related]
2. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
3. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
4. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
5. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
6. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
7. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
8. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
9. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
10. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
11. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.
Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW
Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907
[TBL] [Abstract][Full Text] [Related]
12. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.
Li Y; Li S; Jiang Z; Tan K; Meng Y; Zhang D; Ma X
J Nanobiotechnology; 2023 Jul; 21(1):212. PubMed ID: 37415161
[TBL] [Abstract][Full Text] [Related]
13. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
14. Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.
Biri-Kovács B; Bánóczi Z; Tummalapally A; Szabó I
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839774
[TBL] [Abstract][Full Text] [Related]
15. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
16. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
[TBL] [Abstract][Full Text] [Related]
17. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
18. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
19. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
20. DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
Zhu G; Liu Y; Yang X; Kim YH; Zhang H; Jia R; Liao HS; Jin A; Lin J; Aronova M; Leapman R; Nie Z; Niu G; Chen X
Nanoscale; 2016 Mar; 8(12):6684-92. PubMed ID: 26947116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
